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Genomic imprinting is the differential expression of a gene
depending on the parent of origin. H19 and insulin-like growth
factor-2 (IGF-2) are imprinted genes that map to a 90-kilobase
(kb) region on chromosome 11p15 (Zemel et al, 1992). In the
majority of human tissues, only the maternal allele of the H19
gene is expressed and only the paternal allele of the IGF-2 gene is
expressed. In adult human liver and fetal choroid plexus and
leptomeninges, however, IGF-2 is biallelically expressed (Ohlsson
et al, 1993; Ekstrom et al, 1995).
In human liver, IGF-2 is monoallelically expressed at birth, with a
switch to biallelic expression some time during the first year of post-
natal life (Ohlsson et al, 1993; Davies, 1994; Li et al, 1996). IGF-2
expression is regulated by four promoters, P1–P4, which are
expressed, and hence imprinted, differently. P1 is biallelically
expressed and is active in adult human liver. In fetal and early post-
natal liver, however, the pattern of P1 expression is complex.
Although it has been demonstrated that the P1 promoter directs
expression from both parental alleles in prenatal as well as post-
natal liver specimens (Ekstrom et al, 1995), some studies suggest
that the P1 promoter is not used in early fetal life (Li et al, 1996,
1998), while others have detected P1-derived transcripts in fetal and
newborn liver tissue (Taniguchi et al, 1995; Vu and Hoffman, 1996).
In contrast, promoters P2–P4 are expressed monoallelically and are
used in fetal and infant tissues, but in older infants (> 18 months)
and adults imprinting of P2–P4 exhibits plasticity. Both monoallelic
and biallelic expression have been described, as have instances of
monoallelic expression from opposite parental alleles. Switching
from monoallelic to biallelic IGF-2 expression in normal human
liver in the first year of life involves increased use of P1 and the
development of plasticity in P2–P4. In contrast, H19 is imprinted in
normal human liver throughout life (Ekstrom et al, 1995). The
precise mechanism by which genes and their regulatory elements
are imprinted is currently unknown, although available data suggest
that methylation of DNA may determine the imprint (Hu, 1996).
Biallelic expression of IGF-2 and H19 has been demonstrated in
several paediatric and adult malignancies, including Wilms’
tumour, Ewing sarcoma, embryonal rhabdomyosarcoma, germ cell
tumours, lung cancer, oesophageal cancer, glioma and renal cell
carcinoma (Glassman et al, 1996; Uyeno et al, 1996; Nonomura et
al, 1997; Ross et al, 1999). In contrast, for hepatoblastoma, an
embryonal liver tumour that usually occurs in the first 5 years of
life, monoallelic expression of IGF-2 has generally been reported,
with biallelic expression observed in only a minority of cases
(Davies, 1993; Li et al, 1995; Rainier et al, 1995). In this study, we
examined expression of IGF-2 and H19 in informative tumour
specimens and normal matched tissue (if available) from children
of different ages diagnosed with hepatoblastoma.
MATERIALS AND METHODS
Tumour samples
Hepatoblastoma tissue (and normal matched tissue, if available),
frozen at –70°C, was obtained from the Cooperative Human
Tissue Network (CHTN; Columbus, OH, USA). Tissue underwent
institutional and central pathological review to ensure uniformity
of diagnosis. Normal liver tissue from a 14-year-old traffic acci-
dent victim was obtained from the Liver Tissue Procurement and
Distribution System (NIH Grant N01-DK-6-2274).
Allele-specific gene expression
Genomic DNA (gDNA) was extracted using standard techniques,
and samples were screened for heterozygosity for a known ApaI
polymorphism within exon 9 of IGF-2 as previously described
(Ogawa et al, 1993). If heterozygous (and hence informative),
reverse transcription polymerase chain reaction (RT-PCR) was
performed as described by Nonomura et al (1997). PCR products
were digested with ApaI (yielding either a 236-bp fragment or a
173- and 63-bp fragment), electrophoresed through a 1.5% agarose
gel, and visualized with ethidium bromide. To monitor for gDNA
contamination of the cDNA preparation, RT-PCR was performed
both with and without reverse transcriptase; no amplification was
observed from samples without reverse transcriptase (Figure 1A).
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al (1996) (Figure 2). In brief, a multiplex PCR was performed in
which cDNAs were amplified using four promoter-specific 5¢-
primers and a common 3¢-primer end-labelled with [g-32P]ATP.
Oligonucleotide primers used were: CAGTCCTGAGGTGAGCT-
GCTGTGGC (hP1), ACCGGGCATTGCCCCCAGTCTCC (hP2),
CGTCGCACATTCGGCCCCCGCGACT (hP3), TCCTCCTCCT-
CCTGCCCCAGCG (hP4), CAGCAATGCAGCACGAGGCGA-
AGCC (3¢ primer).
Amplification of H19 was performed as described by Uyeno et
al (1996). PCR products were digested with RsaI (yielding either a
655-bp product or a 485- and 170-bp fragment). If heterozygous,
cDNA was reverse transcribed and amplified in the same manner
as gDNA producing 575- or 405-bp products after digestion with
RsaI. As the primers span the last intron of H19, gDNA contami-
nation is excluded by the absence of a 655 bp product (Figure 1B).
For all experiments, PCR amplification and digests were
repeated in duplicate to exclude the possibility of incomplete
digestions yielding misleading results. In addition, all samples
were digested in the presence of a positive control homozygous for
the smaller fragment to ensure complete digestions. To monitor for
potential cross-sample DNA contamination of PCR reactions,
control amplifications were performed without DNA template and
were shown to be negative for each experiment.
RESULTS
Genomic DNA from 30 hepatoblastomas was amplified by PCR
and digested with ApaI and RsaI to identify the presence of previ-
ously described polymorphisms in IGF-2 and H19 respectively
(Ogawa et al, 1993; Rainier et al, 1993). Thirteen (43%) tumours
were informative (heterozygous) for H19, and 13 were informa-
tive for IGF-2. Six (20%) hepatoblastomas were heterozygous for
both IGF-2 and H19. Four tumours had normal adjacent liver
tissue available (Table 1). Demographic data on individuals with
these informative tumours are provided in Table 1. The majority
(80%) of patients were male and the median age at diagnosis was
1.8 years (range 1 month to 9 years).
For all tissue examined (including both malignant and normal
adjacent liver tissue), H19 was monoallelically expressed. In
contrast, variable patterns of allele-specific expression at IGF-2
were observed. The majority (10/13) of informative tumours
demonstrated monoallelic expression of IGF-2. Tumours demon-
strating biallelic expression of IGF-2 (E, I and T) were diagnosed
in children aged 10 months, 18 months and 9 years respectively. In
two cases (J and L; diagnosed at ages 18 months and 2 years)
normal adjacent liver tissue showed biallelic expression of IGF-2,
while expression was monoallelic in the tumour tissue. However,
two others (G and M; diagnosed at ages 13 months and 2 years)
showed monoallelic IGF-2 expression in tumour tissue and in
adjacent normal liver tissue.
Examination of IGF-2 promoter usage in the adjacent normal
liver tissue of G and M showed usage of all promoters, including
P1 (Figure 2).
DISCUSSION
This study represents one of the largest investigations of H19 and
IGF-2 allele expression in hepatoblastoma. Allele-specific expres-
sion in hepatoblastoma is of particular interest since monoallelic
expression of IGF2 is typically observed in normal fetal liver, with
a change to biallelic expression occurring during the first year of
life. This pattern is in direct contrast to that observed in most other
normal tissues where monoallelic expression of IGF-2 continues
throughout life. We examined allele-specific expression of IGF-2
and H19 in a wide age range of hepatoblastomas including chil-
dren diagnosed in the first few months of life, as well as tumours
diagnosed at 2 years of age or greater, where biallelic IGF-2
expression is expected in normal liver.
We found monoallelic expression of H19 was maintained in all
tissue (malignant and normal) studied. Few previous studies have
specifically examined H19 allele expression in hepatoblastoma.
Rainier et al (1995) examined five hepatoblastomas and found that
H19 was biallelically expressed in one tumour that demonstrated
biallelic expression of IGF-2. In contrast, in a study of three
tumours, Li et al (1995) reported that monoallelic expression was
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Figure 1 (A) IGF-2, tumour J. Each panel contains nine lanes: Lane 1
contains primer-amplified gDNA, Lane 2 contains primer amplified gDNA
digested with Apal to demonstrate heterozygosity, Lane 3 is a control to
monitor for gDNA contamination of the tumour cDNA product (cDNA without
reverse transcriptase), Lane 4 contains primer-amplified cDNA product, Lane
5 contains primer-amplified cDNA tumour product digested with Apal, Lane 6
is a control to monitor for gDNA contamination of cDNA from normal liver
adjacent to the tumour, Lane 7 contains primer-amplified cDNA from normal
tissue, and Lane 8 contains primer-amplified cDNA from normal tissue
digested with Apal (B) H19, tumour L. Each panel contains nine lanes: Lane
1 contains primer-amplified gDNA, Lane 2 contains primer amplified gDNA
digested with Rsal to demonstrate heterozygosity, Lane 3 is a control to
monitor for gDNA contamination of the tumour cDNA product (cDNA without
reverse transcriptase), Lane 4 contains primer-amplified cDNA product, Lane
5 contains primer-amplified cDNA tumour product digested with the Rsal,
Lane 6 is a control to monitor for gDNA contamination of cDNA from normal
liver tissue adjacent to the tumour, Lane 7 contains primer-amplified cDNA
from normal tissue, and Lane 8 contains primer-amplified cDNA from normal
tissue digested with Rsal
P4
P1
P3
P2
Figure 2 IGF-2 promoter usage. Lane 1 contains a size marker, Lane 2
contains promoter-specific primer amplified cDNA product (P2 = 277 bp, P3 =
211 bp, P1 = 186 bp, P4 = 119 bp) of liver tissue obtained from a 14-year-old
traffic accident victim, Lanes 3, 5 and 7 are controls to monitor for gDNA
contamination of the cDNA product, Lane 4 contains promoter-specific primer
amplified cDNA product from normal liver tissue adjacent to tumour M, Lane
6 contains promoter-specific primer amplified cDNA product from normal liver
tissue adjacent to tumour G, Lane 8 is a PCR-negative control. (Although P2
appears faint in Lane 6, it is clearly apparent with longer exposure)maintained for H19 in a tumour that demonstrated biallelic expres-
sion of IGF-2. Given that all of our informative hepatoblastomas
demonstrated monoallelic expression at H19, it is unlikely that
alterations in allele-specific expression of H19 plays a major role
in the development of hepatoblastoma.
In contrast to H19, variable patterns of allele-specific expression
of IGF-2 were observed. The majority of tumours in our study
demonstrated monoallelic expression of IGF-2, supporting observa-
tions reported in smaller studies (Davies, 1993; Li et al, 1995;
Rainier et al, 1995). Biallelic expression of IGF-2 in malignant
tissue at most sites is abnormal and is considered part of the
malignant phenotype, potentially contributing to the progression of
disease. In contrast, biallelic expression of IGF-2 is considered
normal in post-natal human liver and fetal choroid plexus/
leptomeninges (Ekstrom et al, 1995). Switching from the fetal
pattern of monoallelic IGF-2 expression to biallelic expression in
normal human liver development entails increased use of the biallel-
ically expressed promoter P1, together with plasticity of imprinting
of P2–P4 (Li et al, 1998). The precise age at which this typically
occurs is controversial and has only been studied in a small number
of cases. Some studies suggest that biallelic IGF-2 expression begins
between 6 months and 1 year post-natal age (Ohlsson et al, 1993;
Davies, 1994), whereas others observed biallelic IGF-2 expression
in the liver tissue of a 2-month-old (Li et al, 1996). In the latter
study, however, the tissue evaluated was adjacent normal liver from
a child with hepatoblastoma, which may not be appropriate for
determination of developmental patterns in healthy individuals.
In our study, the observation of monoallelic IGF-2 expression in
hepatoblastoma tissue at ages when normal liver expresses IGF-2
biallelically (tumours J, K, L, M, N, P; all 18 months of age or
older) may indicate a failure to follow the normal sequence of
change in promoter usage (e.g. increased usage of P1). In such
cases, it is possible that carcinogenesis is initiated at an earlier
developmental time point than in cases in which normal progres-
sion to biallelic usage is seen. Moreover, the observation of
monoallelic IGF-2 expression in normal liver adjacent to hepato-
blastoma may indicate premalignant change in a larger area of 
the liver than that morphologically involved with tumour.
Nevertheless, for the two cases (G and M; ages 13 months and 
2 years) that showed monoallelic expression of IGF-2, all four
promoters were utilized in the normal adjacent liver tissue. If the
age at which promoter switching occurs is more variable than that
reported to date, it is possible that the normal liver in these cases
has simply not undergone the switch from monoallelic to biallelic
IGF-2 expression and that the allele usage observed in both tumour
and normal liver is appropriate, and not related to the malignant
phenotype. Clearly, larger studies of normal liver tissue obtained
in the first few years of life are needed to accurately evaluate the
variability of timing of promoter silencing and switching of IGF-2.
In malignancies other than hepatoblastoma, allele-specific
expression patterns for H19 and IGF-2 appear to vary, with
coupling of expression frequently observed. For example, in testic-
ular germ cell tumours (both paediatric and adult), as well as in
Wilms’ tumour, biallelic expression of both H19 and IGF-2 has
been frequently observed (van Gurp et al, 1994; Nonomura et al,
1997, Ross et al, 1999). In childhood embryonal tumours in partic-
ular, biallelic expression of IGF-2 is thought to be related to
elevated levels of IGF-2 production, and potentially to contribute
to growth and progression of the tumour (Leisenring et al, 1994).
An alternative interpretation of these data is that biallelic expres-
sion of IGF-2 represents non-specific gene dysregulation, perhaps
due to genome-wide hypomethylation as part of the malignant
phenotype as was shown in hepatocellular carcinoma (Takeda 
et al, 1996; Li et al, 1997). While our data regarding hepatoblas-
tomas could represent non-specific dysregulation of gene expres-
sion, the continuation of monoallelic expression would argue
against hypomethylation as a mechanism. Li et al (1995) suggest
that for hepatoblastoma (unlike Wilms’ tumour) the level of H19
expression is not a prerequisite for maintaining a monoallelic IGF-
2 expression. Moreover, as in our study, they report monoallelic
expression of H19 in a case of hepatoblastoma that showed
biallelic expression of IGF2.
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Table 1 Allelic usage of IGF2 and H19 in 20 informative hepatoblastoma tumours
ID Gender Normal Age at Dx IGF-2 H19 IGF-2 H19 IGF-2 H19
tissue informative informative (malignant (malignant (normal (normal
tissue) tissue) adjacent adjacent
tissue) tissue)
A M 1 months Yes No Monoallelic
B M 7 months Yes Yes Monoallelic Monoallelic
C M 8 months No Yes Monoallelic
D M 10 months No Yes Monoallelic
E F 10 months Yes Yes Biallelic Monoallelic
F M 12 months Yes Yes Monoallelic Monoallelic
G M Yes 13 months Yes No Monoallelic Monoallelic
H F 15 months No Yes Monoallelic
I M 18 months Yes No Biallelic
J M Yes 18 months Yes Yes Monoallelic Monoallelic Biallelic Monoallelic
K F 2 years Yes No Monoallelic
L F Yes 2 years Yes Yes Monoallelic Monoallelic Biallelic Monoallelic
M M Yes 2 years Yes Yes Monoallelic Monoallelic Monoallelic Monoallelic
N F 2 years Yes No Monoallelic
O F 2 years No Yes Monoallelic
P M 2.5 years Yes No Monoallelic
Q M 2.5 years No Yes Monoallelic
R M 3 years No Yes Monoallelic
S M 4 years No Yes Monoallelic
T M 9 years Yes No BiallelicIn summary, we conclude that monoallelic expression of H19 is
maintained in the vast majority of hepatoblastomas, suggesting
that alterations of allele-specific expression of H19 are unlikely to
play a major role in carcinogenesis at this site. Moreover, we
report variable allele-specific expression patterns for IGF-2 with
respect to age at diagnosis. To further understand the importance
of IGF-2 allele-specific expression in the malignant phenotype,
larger studies evaluating the age at which the switch from mono-
allelic to biallelic IGF-2 expression occurs in normal liver are
warranted.
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